Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors.
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
L.S. Harrington and G.M. Findlay contributed equally to this paper.
Abbreviations used in this paper: IRS, insulin receptor substrate; MEF, mouse embryo fibroblast; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-OH kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PTB, phosphotyrosine-binding domain; siRNA, small interfering RNA; TSC, tuberous sclerosis complex.
Laura S. Harrington, Greg M. Findlay, Alex Gray, Tatiana Tolkacheva, Simon Wigfield, Heike Rebholz, Jill Barnett, Nick R. Leslie, Susan Cheng, Peter R. Shepherd, Ivan Gout, C. Peter Downes, Richard F. Lamb; The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins . J Cell Biol 19 July 2004; 166 (2): 213–223. doi: https://doi.org/10.1083/jcb.200403069
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement